Syed Rayyan Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Syed Rayyan Ahmed has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Hasnain Azeem
Dow University of Health Sciences, Karachi, Pakistan
5 shared publications - Danish Hassan
Dow Medical College, DUHS, Karachi, Pakistan
4 shared publications - Alishba Fatima
Dow University of Health Sciences, Karachi, Pakistan
3 shared publications - Emad Uddin Sajid
Department of Medicine Dow University of Health Sciences Karachi Pakistan
3 shared publications - Rida Shakeel
Department of Surgery, Dow Medical College, Karachi, Pakistan
3 shared publications - Abdullah Shahbaz
Dow Medical College, DUHS, Karachi, Pakistan
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (6)
Rising Atrial Fibrillation Mortality Trends in Hypertensive Patients Aged 25 and Older: A CDC Wonder Database Analysis
Background: Atrial fibrillation (AF) is a leading arrhythmia contributing to cardiovascular mortality, particularly among individuals with Hypertension (HTN), yet long‐term trends and disparities remain underexplored. We analyzed national patterns and sociodemographic differences in AF‐related mortality among US adults aged 25 years or older from 1999 to 2023. Methods: We used CDC WONDER mortality data (1999–2023) to analyze AF‐related deaths among US adults aged ≥ 25 with HTN. Age‐adjusted mortality rates (AAMR) per 100 000 and average annual percent changes (AAPC) were calculated using Joinpoint regression to assess overall and subgroup‐specific trends. Results: AF accounted for 1 108 265 deaths among adults with HTN, with AAMRs increasing from 3.8 in 1999 to 35.9 in 2023 (AAPC: 6.03%). The sharpest rise occurred from 2018 to 2021, with an APC of 14.57%, coinciding with the COVID‐19 pandemic. Men had higher AAMRs than women (20.5 vs. 17.1). Racial disparities were evident, with non‐Hispanic Whites having the highest AAMR (20.1), followed by non‐Hispanic Blacks (15.1), Hispanics (11.3), and non‐Hispanic Others (10.7). Regional variation showed that the West had the highest AAMR (20.8), while Vermont recorded the highest state rate (28.7), and Nevada had the lowest (11.4). Rural areas exhibited higher mortality rates than urban areas (17.8 vs. 16.1), with rural AAMRs increasing at a faster rate (AAPC: 10.61%). Conclusion: The rising burden of AF‐related mortality in hypertensive patients, especially among men, non‐Hispanic Whites, and rural populations, signals a critical public health concern. Immediate, equity‐focused interventions are needed to mitigate disparities and reduce AF‐related mortality across the United States.
- 18 November 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (6)
Open AccessRising Atrial Fibrillation Mortality Trends in Hypertensive Patients Aged 25 and Older: A CDC Wonder Database Analysis
Background: Atrial fibrillation (AF) is a leading arrhythmia contributing to cardiovascular mortality, particularly among individuals with Hypertension (HTN), yet long‐term trends and disparities remain underexplored. We analyzed national patterns and sociodemographic differences in AF‐related mortality among US adults aged 25 years or older from 1999 to 2023. Methods: We used CDC WONDER mortality data (1999–2023) to analyze AF‐related deaths among US adults aged ≥ 25 with HTN. Age‐adjusted mortality rates (AAMR) per 100 000 and average annual percent changes (AAPC) were calculated using Joinpoint regression to assess overall and subgroup‐specific trends. Results: AF accounted for 1 108 265 deaths among adults with HTN, with AAMRs increasing from 3.8 in 1999 to 35.9 in 2023 (AAPC: 6.03%). The sharpest rise occurred from 2018 to 2021, with an APC of 14.57%, coinciding with the COVID‐19 pandemic. Men had higher AAMRs than women (20.5 vs. 17.1). Racial disparities were evident, with non‐Hispanic Whites having the highest AAMR (20.1), followed by non‐Hispanic Blacks (15.1), Hispanics (11.3), and non‐Hispanic Others (10.7). Regional variation showed that the West had the highest AAMR (20.8), while Vermont recorded the highest state rate (28.7), and Nevada had the lowest (11.4). Rural areas exhibited higher mortality rates than urban areas (17.8 vs. 16.1), with rural AAMRs increasing at a faster rate (AAPC: 10.61%). Conclusion: The rising burden of AF‐related mortality in hypertensive patients, especially among men, non‐Hispanic Whites, and rural populations, signals a critical public health concern. Immediate, equity‐focused interventions are needed to mitigate disparities and reduce AF‐related mortality across the United States.
- Open Access
- 27 July 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (8)
Mortality Trend in Patients With Heart Failure and Psychoactive Substance Abuse in the United States—Pre‐ and Post‐COVID‐19 Pandemic Perspective (1999−2023)
Background: This study evaluates national trends in heart failure (HF) and psychoactive substance abuse‐related mortality among adults aged 25 years and older in the United States (US) from 1999 to 2023, stratified by sex, age, race/ethnicity, geographic regions, and the COVID‐19 pandemic period. Methods: Data from 1999 to 2023 were extracted from the CDC WONDER database. Age‐adjusted mortality rates (AAMR) and annual percentage changes (APC) were calculated using Joinpoint regression. ICD‐10 codes I50, I50.1, I50.9 (Heart Failure), and F10‐19 (Psychoactive Substance Use) were used to identify the conditions. Results: A total of 771 739 deaths were recorded from 1999 to 2023 among individuals aged 25 and older. Most deaths occurred in medical facilities (39.24%), followed by decedents' homes (34.14%), long‐term care facilities (16.30%), hospice (6.65%), and other settings (3.67%). The AAMR increased markedly from 1.68 in 1999 to 20.7 in 2023 (AAPC of 12.09, 95% confidence interval [CI]: 10.97−14.26). A substantial increase was observed from 1999 to 2005 (APC: 38.5%, 95% CI: 29.1–55.8), followed by a slower increase until 2020 (APC: 5.68%, 95% CI: 5.02–14.8). Men showed consistently higher AAMRs than females (18.8 vs. 8.65). By age group, mortality was highest among individuals aged 65 years and older. Conclusion: Using CDC WONDER data (1999–2023), we found a sharp rise in HF mortality linked to psychoactive substance abuse, from 1.68 to 20.7 per 100 000. Mortality burden was highest among males, older adults, non‐Hispanic White individuals, and rural populations, highlighting widening demographic and geographic disparities.
- 27 July 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (8)
Open AccessMortality Trend in Patients With Heart Failure and Psychoactive Substance Abuse in the United States—Pre‐ and Post‐COVID‐19 Pandemic Perspective (1999−2023)
Background: This study evaluates national trends in heart failure (HF) and psychoactive substance abuse‐related mortality among adults aged 25 years and older in the United States (US) from 1999 to 2023, stratified by sex, age, race/ethnicity, geographic regions, and the COVID‐19 pandemic period. Methods: Data from 1999 to 2023 were extracted from the CDC WONDER database. Age‐adjusted mortality rates (AAMR) and annual percentage changes (APC) were calculated using Joinpoint regression. ICD‐10 codes I50, I50.1, I50.9 (Heart Failure), and F10‐19 (Psychoactive Substance Use) were used to identify the conditions. Results: A total of 771 739 deaths were recorded from 1999 to 2023 among individuals aged 25 and older. Most deaths occurred in medical facilities (39.24%), followed by decedents' homes (34.14%), long‐term care facilities (16.30%), hospice (6.65%), and other settings (3.67%). The AAMR increased markedly from 1.68 in 1999 to 20.7 in 2023 (AAPC of 12.09, 95% confidence interval [CI]: 10.97−14.26). A substantial increase was observed from 1999 to 2005 (APC: 38.5%, 95% CI: 29.1–55.8), followed by a slower increase until 2020 (APC: 5.68%, 95% CI: 5.02–14.8). Men showed consistently higher AAMRs than females (18.8 vs. 8.65). By age group, mortality was highest among individuals aged 65 years and older. Conclusion: Using CDC WONDER data (1999–2023), we found a sharp rise in HF mortality linked to psychoactive substance abuse, from 1.68 to 20.7 per 100 000. Mortality burden was highest among males, older adults, non‐Hispanic White individuals, and rural populations, highlighting widening demographic and geographic disparities.
- Open Access
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Open AccessModerate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- Open Access
- 13 May 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (5) , e70346
Comment on “Updated Meta‐Analysis of Left Bundle Branch Area Pacing Versus Right Ventricular Pacing in Conduction System Disorders: Insights From New Evidence”
- 13 May 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (5) , e70346
Open AccessComment on “Updated Meta‐Analysis of Left Bundle Branch Area Pacing Versus Right Ventricular Pacing in Conduction System Disorders: Insights From New Evidence”
- 8 May 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 111, 107222
Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review
- 8 May 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 111, 107222
Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review
- RetractedOpen Access
- 10 October 2025
- Published by Elsevier in Archives of Gerontology and Geriatrics Plus
- Vol. 2 (4)
RETRACTED: Trends in stroke mortality among older adults (≥65 years) with chronic kidney disease in the U.S. from 1999 to 2020
- 10 October 2025
- Published by Elsevier in Archives of Gerontology and Geriatrics Plus
- Vol. 2 (4)
RetractedOpen AccessRETRACTED: Trends in stroke mortality among older adults (≥65 years) with chronic kidney disease in the U.S. from 1999 to 2020
- 29 April 2023
- Published by Elsevier in Heart & Lung
- Vol. 61, 161
Comment on: Effects of time of bed rest on vascular complications after cardiac catheterization in pediatric patients with congenital heart disease
- 29 April 2023
- Published by Elsevier in Heart & Lung
- Vol. 61, 161
Comment on: Effects of time of bed rest on vascular complications after cardiac catheterization in pediatric patients with congenital heart disease